Journey Medical (US:DERM) ZACKSยท2025-08-04 15:00Core Viewpoint - Journey Medical Corporation (DERM) is expected to report a year-over-year increase in earnings despite flat revenues, with a consensus estimate of a quarterly loss of $0.07 per share, reflecting a 58.8% improvement compared to the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show revenues of $14.85 million, unchanged from the same quarter last year [3]. - A positive earnings surprise is likely if the actual results exceed these expectations, while a miss could lead to a decline in stock price [2]. Estimate Revisions - The consensus EPS estimate has been revised 100% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Journey Medical is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +14.29%, suggesting a bullish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Journey Medical was expected to post a loss of $0.24 per share but delivered a loss of -$0.18, resulting in a positive surprise of +25.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - Nektar Therapeutics (NKTR), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $2.65 per share, with revenues projected to decline by 54.1% year-over-year [18]. - Nektar's consensus EPS estimate has been revised down by 1.9% in the last 30 days, and it currently has an Earnings ESP of -29.46%, making it difficult to predict a beat on the consensus EPS estimate [19].